key: cord-0734561-x4be97d0
authors: Knopf, Alison
title: 2021: Making COVID‐caused changes permanent, for better or worse
date: 2021-12-31
journal: Alcoholism & Drug Abuse Weekly
DOI: 10.1002/adaw.33300
sha: d0b2dd214965bc7acbb5cdb23973c15b45085b14
doc_id: 734561
cord_uid: x4be97d0

What started in 2020 — COVID‐19 — continued with a vengeance in 2021, but last year, some of the changes put into place due to the virus became permanent, at least for now. These included relaxations of the rules regarding buprenorphine and methadone, far greater use of telemedicine and other less sanguine changes, such as to‐go alcohol. In the meantime, opioid overdoses continued to go up, this time with the addition of methamphetamine and cocaine.

It was also the first full year of President Biden's administration, in which it made many changes, including incorporating more harm reduction into the treatment-prevention mix. In many ways, this filtered down to the states.

Meanwhile, the message from the federal government, while moving toward harm reduction, has been an As harm reductionists find new sources of funding and policy support and identify recovery-focused organizations as natural allies, some are predicting that 2022 will mark a new level of synergy between groups that represent current and former substance users. Could this in turn mean diminished influence for the traditional treatment organizations that still find some of the boldest ideas in harm reduction foreign to their vision?

Or will the treatment community be successful in framing itself to funders and policymakers as friendly to harm reduction, even if providers stop short of embracing concepts such as safe consumption spaces for people who currently use drugs? These questions will occupy the thinking of advocates as the new year begins.

When new categories of federal funding such as the Substance Abuse and Mental Health Services Administration's (SAMHSA's) $30 million in harm-reduction grants become available (see "SAMHSA announces See 2022 page 7

The past year saw a reckoning with as More money from the American Rescue Plan -more than double the total BG dollars in supplemental money in the past few monthscould help addiction treatment (see "American Rescue Plan includes Editor Alison Knopf

Publisher Lisa Dionne Lento 

We invite you to help guide the future of the newsletter through a brief survey. 

Data derived from the Adolescent Brain and Cognitive Development Study bolsters the view that women should be discouraged from using marijuana while pregnant (see "Childhood outcome analysis highlights risks of cannabis use in pregnancy," ADAW, May 17; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33065).

The National Institute on Drug Abuse (NIDA) set 5 mg of THC as the standard cannabis unit for research (see "NIDA sets 5 mg of THC as standard cannabis unit for research," ADAW, May 17; https://onlinelibrary. wiley.com/doi/10.1002/adaw.33068).

The number of college students using marijuana reached its highest level since the 1980s (see "College students use marijuana at highest level since 1980s: MTF," ADAW, Sept. 20; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33194).

Brattleboro Retreat, Vermont's largest addiction treatment organization, continued to adjust to conditions threatening stand-alone treatment with massive layoffs (see "Plight of Brattleboro Retreat highlights challenges for institutions," ADAW, Feb. 15; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32970).

A "secret shopper" study found that many residential treatment programs employed unethical tactics when three researchers, posing as patients, called them saying they wanted to pay with cash only and were addicted to heroin. The lapses, which include what the researchers called excessively high rates for treatment and pitches for so-called luxury services, were particularly evident in for-profit programs. The study, which received widespread media attention, including a piece on National Public Radio Feb. 15, was published in the February issue of Health Affairs.

It focused only on marketing, not clinical quality (see "'Secret shopper' study finds many centers use unethical marketing tactics," ADAW, Feb. 22; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32978).

Indivior and Reckitt Benckiser agreed to a settlement in which Indivior was released from indemnity under the demerger (spinoff) agreement and, in exchange, will give Reckitt Benckiser $50 million over the next five years. Reckitt Benckiser Pharmaceuticals was the original sponsor of buprenorphine; Indivior is the spinoff which now owns it. ("In Case You Haven't Heard…," ADAW, Feb. 22; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32983).

Lagging Medicaid reimbursement rates and the immediacy of the COVID-19 crisis combined to place Phoenix House in severe financial peril, but a relatively new state program offering an alternative to traditional receivership could help the program emerge from this calamity (see "With low census and Medicaid payment, Phoenix House navigates financial crisis," ADAW, Feb. 22; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32979).

Signing an agreement with a managed care company may not seem like a path to profit and good patient care, but for the legendary Caron, it has been working out. Value-based contracting is what it sounds like: giving the insurance company value for its money. But this is not based on limiting days or type of treatment, just dollars. And as long as those dollars are agreed upon, all is well, according to Joseph Garbely, D.O., chief medical officer at Caron, in an interview with ADAW (see "Caron praises VBC; is at risk for 90 days post-discharge," ADAW, May 17; https://onlinelibrary. wiley.com/doi/10.1002/adaw.33066).

The Salvation Army's substance use rehabilitation programs in California violate the state's stringent labor laws by imposing onerous work requirements with little compensation, according to a lawsuit filed in state court (see "Lawsuit: Salvation Army rehab programs subject participants to illegal conditions," ADAW, May 31; https://onlinelibrary. wiley.com/doi/10.1002/adaw.33081).

The Betty Ford Center broke ground for its most significant expansion since opening four decades ago this month. The $30 million expansion and renovation of the Rancho Mirage, California, facility will enable the program to meet an increasing demand for services, including mental illness (see "Betty Ford Center launches $30 million expansion and renovation," ADAW, with the Hampden County Sheriff's Department to provide medications for opioid use disorder (OUD) -methadone, buprenorphine or naltrexone -as well as counseling and behavioral therapy to people in the county jails. The partnership strengthens an alreadyexisting medication-assisted treatment program in the county (see "OTP partners with county sheriff for jail-based MAT," ADAW, March 8; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32993).

At the American Association for the Treatment of Opioid Dependence (AATOD) virtual meeting, attendees learned about the increasing involvement -much needed and welcome -of corrections in the treatment of opioid use disorder (see "How corrections can provide medications for justice-involved individuals with OUD," ADAW, April 19; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33031).

The federal Department of Health and Human Services (HHS) followed up on its proposal to weaken the Health Insurance Portability and Accountability Act (HIPAA), saying patient records should be "shareable," opening up privacy to recordsfor-sale. So much for the people who kept saying "make 42 CFR Part 2 like HIPAA." Here's the Notice of Proposed Rulemaking (NOPR): https:// www.hhs.gov/sites/default/files/ hhs-ocr-hipaa-nprm.pdf (see "In Case You Haven't Heard…," ADAW, Jan. 11; https://onlinelibrary.wiley. com/doi/10.1002/adaw.32940).

Shortly thereafter, the HHS Office for Civil Rights made good on its threat, publishing its NOPR, the "Standards for the Privacy of Individually Identifiable Health Information (Privacy Rule)," in the Jan. 21 Federal Register -a day after President Joe Biden was inaugurated (and a day after the new administration placed a freeze on rulemakings) (see "HHS proceeds with weakening of HIPAA, including for SUD," ADAW, Feb. 1; https://onlinelibrary.wiley. com/doi/10.1002/adaw.32958).

The 2011 "Dear Colleague Letter" to OTPs requiring them to check with prescription drug monitoring programs (PDMPs) but banning them from putting patient information into them is still valid. Everyone was waiting for the CARES shoe to drop on 42 CFR Part 2, but SAMHSA surprised us by announcing on April 9 -just as the AATOD conference was beginning -that the confidentiality regulation would remain in place until the agency promulgates a rulemaking. For the SAMHSA statement, go to https://www.samhsa.gov/newsroom/statements/2021/42-cfr-part-2-amendments-process (see "42 CFR Part 2 still in effect, regardless of CARES Act," ADAW, April 19; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33036).

The federal government plans to limit or eliminate HIPAA privacy provisions, with grave implications for SUD patients and providers (see "HHS-proposed rule gutting HIPAA would especially hurt patients with SUD," ADAW, May 17; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33064).

A report showed that applications for SUD don't safeguard confidentiality (see "Confidentiality in spotlight with report on OUD apps and LAC comment on CARES Act," ADAW, July 19; https://onlinelibrary.wiley. com/doi/10.1002/adaw.33133).

It's well known that contingency management, in which patients are given monetary rewards for negative drug tests, is the best -i.e., most effective -treatment for stimulant use disorders. The final rule banning higher payments was published in January (see "In Case You Haven't Heard," ADAW, March 22; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33015).

The emergence of stimulants as a critical component of the latest wave of the opioid crisis brings added complexity because of a significant knowledge gap regarding stimulants, a leading researcher said (see "Latest iteration of the opioid crisis may be the toughest yet to combat," ADAW, authority in managing the publicly funded addiction treatment, prevention and recovery service system, as well as using innovative approaches to adapt to the pandemic (see "Stringer to Congress: COVID effects on substance use," ADAW, March 29; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33019).

Whether opioid settlement money is used for treatment will be up to each state (see "Opioid settlement money for treatment? It's up to the states," ADAW, Sept. 13; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33186).

A study of counselor attitudes about an "open-access" methadone program they worked in found that patients and counselors benefit from same-day access and making treatment more individualized to patient needs. However, downsides were that for clinicians, some patients needed extra care and sometimes intensive interventions, making workload unpredictable, and the increased census resulted in some "chaos" in the building (see "Counselors approve of easy access to methadone treatment: Study," ADAW, Jan. 18; https://onlinelibrary.wiley. com/doi/10.1002/adaw.32941).

For the first time in years, light was shed on central registries last year. Central registries were created to prevent dual enrollment in opioid treatment programs (OTPs). States that had central registries at all managed them or contracted them out. Central registries were born of the confidentiality rule, 42 CFR Part 2, making an exemption for sharing patient information so that patients would not go to more than one methadone program at a time. For decades they went along doing their job (especially in New York state, where the central registry is ironclad in terms of protecting patient data). ADAW had a three-part series on how central registries work (see "Central registries: What are they? Part 1," ADAW,

Central registries, Part 2: The role of a national registry

Mobile methadone has been approved for licensed OTPs (see "Mobile methadone now approved for licensed OTPs

The Drug Enforcement Administration (DEA) outlined the rules for the newly approved methadone vans at a recent AATOD-hosted meeting (see "Methadone van details outlined at AATOD webinar

Planned legislation that would allow pharmacies to distribute methadone and increase the volume of take-home doses was announced by Rep. Donald Norcross (D-New Jersey). In a move that has been described as "modernization

The training requirement for buprenorphine prescribers was removed by outgoing federal officials days before they left office in January 2021; the former official in charge, Elinore McCance-Katz, M.D., Ph.D., had fought to keep the requirement for years. She told ADAW why (see "Trump's HHS eliminates x-waiver in last days of administration," ADAW, Jan. 25; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32949).An unprecedented coalition of treatment and recovery organizations has written the HHS and the ONDCP requesting the development of "improved training platforms to replace waiver training prior to waiver elimination." The Feb. 18 letter, a copy of which was obtained by ADAW, supported President Biden's goal of increasing access to the use of methadone, naltrexone and buprenorphine. It's buprenorphine, however, that was at issue in this letter (see "Coalition requests buprenorphine training before HHS acts on waiver," ADAW, March 1; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32984).Enter the "dabblers": The elimination of the x-waiver for buprenorphine prescribing, which may take place based on stakeholder (insurance, treatment, Congress) forces, will likely result in a spectrum of prescribers, from "dabblers" to fulltime addiction treatment providers, according to a recent commentary by top researchers (see "Enter the 'dabblers': Buprenorphine prescribing if x-waiver is eliminated," ADAW, April 26; https://onlinelibrary.wiley. com/doi/10.1002/adaw.33040).Various formulations of buprenorphine produce various results, but treatment of individuals depends on clinical needs. (see "Which is better: weekly, monthly or daily buprenorphine?" ADAW, July 4; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33123).

Supervised injection facilities are promising in the reduction of opioid overdoses -at least in the only two Continued from page 5 sites in the world where they have been studied -according to a January report issued by the Institute for Clinical and Economic Review (see "Report finds promise in SIFs based on Vancouver and Sydney," ADAW, March 1; https://onlinelibrary.wiley. com/doi/10.1002/adaw.32987).The National Council for Behavioral Health announced March 17 that it will administer $500,000 in grants, with support from the CDC, to harm-reduction organizations across the country (see "National Council distributes $500K in HR grants from CDC," ADAW, March 23; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33012).With harm reduction no longer considered a taboo term across the board, more government and private entities are embracing opportunities to fund growth in harm-reduction organizations (see "An improved funding picture spells hope for harm-reduction workforce," ADAW, May 10; https://onlinelibrary.wiley. com/doi/10.1002/adaw.33058).New York City's first two overdose prevention centers that include safe injection space are now in operation, but questions remain about their sustainability (see "OPCs in New York City could serve as tipping point, though questions remain," ADAW, Dec. 13; https://onlinelibrary.wiley. com/doi/10.1002/adaw.33287).The federal government held its first harm-reduction summit, and while there were painful breakout groups in which treatment representatives were attacked, it was also a chance for stakeholders to discuss issues and, as one observer told us, for drug-use advocates to "show their true colors." It's going to be a difficult time for the harm-reduction advocates who wanted more than what the federal government is planning to call harm reduction: fentanyl test strips, naloxone and syringe services (see "SAMHSA, CDC and ONDCP hold first federal harmreduction summit," ADAW, Dec. 20; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33293).

Programs in New York City and upstate New York would like to see buprenorphine treatment initiation through telemedicine remain in place post-pandemic, saying it is benefiting disadvantaged populations (see "Programs cite improved access under telehealth initiation to buprenorphine," ADAW, March 1; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32985).The benefits of telehealth for treating opioid use disorder are by now well accepted, but what if the patient is postpartum? There are really two patients -the mom who needs treatment and the baby (see "In Case You Haven't Heard," ADAW, May 10; https://onlinelibrary.wiley. com/doi/10.1002/adaw.33063).A report issued in September by SAMHSA focused on the importance of using telemedicine to treat SUDs as well as mental illness. A helpful chart showed the differences between synchronous (real-time) and asynchronous (any-time) treatment sessions, and how they can be used for patients (see "SAMHSA issues report on use of telemedicine," ADAW, Oct. 11; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.33220).Telehealth is helpful for addiction treatment engaging (first-time patients), but a report shows there is no evidence it is better than in-person treatment for retention or effectiveness (see "Telehealth effectiveness for addiction: Jury is still out," ADAW, Oct. 18; https://onlinelibrary.wiley. com/doi/10.1002/adaw.33227).NAATP supports telehealth, with conditions (see "NAATP supports telehealth, with conditions," ADAW, Oct. 25; https://onlinelibrary.wiley. com/doi/10.1002/adaw.33238).

A report from Kaiser Health News (KHN) found that while the pandemic has led to relapse for "thousands of recovering alcoholics," hospitals across the nation have reported steep increases in admissions for alcoholrelated diseases like alcoholic hepatitis and liver failure. These are critical diseases. Even before the pandemic, liver disease related to alcoholism was increasing, with hospitalizations doubling over the past 10 years. National figures were not available, according to KHN, for alcohol liver disease admissions during the epidemic. But at Keck Hospital of the University of Southern California, these admissions were up 30% in 2020 compared with 2019. This condition is often best treated by difficultto-obtain transplants (see "Pandemic linked to rise in alcoholic hepatitis and liver failure," ADAW, March 1; https://onlinelibrary.wiley.com/ doi/10.1002/adaw.32988). • Maternal-Fetal Medicine) , and that at least one medical school will establish a full academic Department of Addiction Medicine … and that these will mark a trend, with more